Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract
N/A
N/A
Both
Colorectal Cancer
Trial Information
Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract
OBJECTIVES:
- Quantify T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) from
the peripheral blood of patients with colon cancer.
OUTLINE: This is an open-label study.
Patients undergo blood collection at time of follow-up, surgery, thoracentesis,
paracentesis, or leukapheresis (≤ 5 times per year). Blood is analyzed for tumor peptides
(carcinoembryonic antigen and MUC1), circulating cytokines, and lymphocyte response by
ELISA, ELISPOT, or intracellular flow.
PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of colon cancer
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1)
Outcome Time Frame:
3 months
Safety Issue:
No
Principal Investigator
Michael Demeure, MD
Investigator Role:
Study Chair
Investigator Affiliation:
University of Arizona
Authority:
United States: Food and Drug Administration
Study ID:
04-0331-01
NCT ID:
NCT00900432
Start Date:
July 2004
Completion Date:
December 2008
Related Keywords:
- Colorectal Cancer
- recurrent colon cancer
- stage I colon cancer
- stage II colon cancer
- stage III colon cancer
- stage IV colon cancer
- Colonic Neoplasms
- Colorectal Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
Name | Location |
|---|---|
| Arizona Cancer Center at University of Arizona Health Sciences Center | Tucson, Arizona 85724 |
